11 results
8-K
EX-99.1
COYA
Coya Therapeutics Inc
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
will leverage his over two decades of clinical development expertise to guide and oversee all of Coya’s development programs, including its lead asset, COYA
10-K
2022 FY
COYA
Coya Therapeutics Inc
29 Mar 23
Annual report
4:08pm
Medicaid rebate liability;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical
424B4
COYA
Coya Therapeutics Inc
30 Dec 22
Prospectus supplement with pricing info
4:17pm
increasing a manufacturer’s Medicaid rebate liability;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities
S-1/A
c02mzpfmbsctj2dnp 53
5 Dec 22
IPO registration (amended)
8:16am
S-1
0xotm ctt
18 Nov 22
IPO registration
5:06pm
DRS/A
ixr0lbk2 9r1chu9
28 Oct 22
Draft registration statement (amended)
12:00am
DRS/A
doxz96m1fjpj xdbr7l
7 Oct 22
Draft registration statement (amended)
12:00am
DRS
74cmwz3rtjxb7bz
19 Aug 22
Draft registration statement
12:00am
- Prev
- 1
- Next